Tranzyme Pharma named two new board members on Wednesday.
Tranzyme, a drug discovery and development firm that deals with gastrointestinal diseases, added Daniel Veber and Jean-Paul Castaigne as independent directors.
Veber, an independent consultant, served as director of medicinal chemistry for SmithKline Beecham (now GSK) from 1993 to 2002. He also worked for Merck for 29 years. He is recognized for peptide and pedtidomimetic chemistry and has earned several patents.
Castaigne is vice president of development and chief scientific officer at Conjuchem, Inc., a drug discovery and development company. He has also worked for Fournier Group, Novartis and other firms.
“Tranzyme has strategically positioned key resources and personnel to achieve our objective of entering Phase I clinical trials by the end of 2005,” said Vipin Garg, president and CEO of Tranzyme. “Dr. Veber is a medicinal chemist with an intimate understanding of our proprietary small molecule chemistry technology, while Dr. Castaigne brings executive level expertise in growing emerging, product-focused companies like ours. They are excellent additions to our Board and will assist us greatly in the next phase of our development.”